Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
44 hedge funds and large institutions have $8.59M invested in Evofem Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 34 closing their positions.
225% more call options, than puts
Call options by funds: $3.83M | Put options by funds: $1.18M
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
13% less capital invested
Capital invested by funds: $9.84M → $8.59M (-$1.26M)
35% less funds holding
Funds holding: 68 → 44 (-24)
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$4.26M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.22M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.45M |
| 4 |
Citigroup
New York
|
+$1.21M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$313K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCP
Mirador Capital Partners
Pleasanton,
California
|
-$955K |
| 2 |
D.E. Shaw & Co
New York
|
-$167K |
| 3 |
JCP
JB Capital Partners
Armonk,
New York
|
-$118K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$74.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$43.6K |
EVFM Hedge Fund Activity: Q2 2022 in Review
44 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2022, worth a combined $8.59M — down 13% from $9.84M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of EVFM and 10 opened new positions — a net loss of 24 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.26M. The largest seller was Mirador Capital Partners, exiting entirely with an estimated $955K sold.
- 44 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2022, down from 68 in Q1 2022.
- Funds reported $8.59M of Evofem Biosciences, Inc. Common Stock stock for Q2 2022, down 13% quarter-over-quarter.
- 10 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2022 and 34 closed out, a net change of -24 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2022 was Baker Bros. Advisors, an estimated $4.26M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2022 was Mirador Capital Partners, an estimated $955K sold.
Based on aggregated 13F filings for Q2 2022.